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BACKGROUND: In patients with multiple myeloma, renal impairment (RI) at the time of diagnosis is associated with
poor survival. To the authors’ knowledge, the current retrospective analysis presented is the first to assess the impact
of various degrees of renal dysfunction on safety and efficacy outcomes in a large cohort of patients with relapsed
and/or refractory multiple myeloma who received treatment with lenalidomide plus dexamethasone. METHODS:
Three hundred fifty-three patients from 2 large phase 3 trials were randomized to receive lenalidomide (25 mg) plus
dexamethasone (40 mg). For the purpose of this analysis, RI was defined according to the calculated creatinine
clearance (CLCr) level as follows: mild or no RI (CLCr   60 mL/minute), moderate RI (CLCr from   30 mL/minute to
<60 mL/minute), and severe RI (CLCr <30 mL/minute). RESULTS: The RI subgroups did not differ significantly
in terms of the overall response rate (range, 50%-64%) or response quality (very good partial response or better,
27%-37%). In all RI subgroups, the time to progression and progression-free survival did not differ significantly com-
pared with the mild or no RI group. Patients with RI experienced an increased incidence of thrombocytopenia,
required more frequent lenalidomide dose reduction or interruption, and had shorter overall survival than patients
with mild or no RI (P ¼ .006). Lenalidomide plus dexamethasone led to improvement in renal function in the majority
of patients. CONCLUSIONS: The results from this study indicated that, with careful monitoring of the CLCr level and
adverse events as well as appropriate dose adjustments, lenalidomide plus dexamethasone is an effective and well
tolerated treatment option for patients with multiple myeloma who have RI. Cancer 2010;116:3807–14. V C 2010 Ameri-
can Cancer Society.
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Approximately 20% of patients with newly diagnosed multiple myeloma (MM) present with renal failure.
1
Moreover, this end-organ damage is the second most common cause of death in patients with MM.
2 Cast nephropathy,
the most common cause of myeloma-associated renal injury, occurs in at least 30% of patients.
2,3 Other causes of renal
impairment(RI)in patientswithMMincludeacute tubulopathy,amyloidlight-chainamyloidosis, light-chain deposition
disease, tubulointerstitial nephritis associated with monotypic light-chain deposits, and plasma cell tumor nodules.
2 In
addition, hypercalcemia, which may impact renal function, occurs in 33% of newly diagnosed patients.
4-6 The degree of
DOI: 10.1002/cncr.25139, Received: November 3, 2009; Revised: November 3, 2009; Accepted: November 3, 2009, Published online May 24, 2010 in Wiley Inter-
Science (www.interscience.wiley.com)
Corresponding author: Meletios Dimopoulos, MD, Department of Clinical Therapeutics, University of Athens School of Medicine, Alexandra Hospital, 80 Vas.
Sofias, 11528 Athens, Greece; Fax: (011) 30-210-3381511; mdimop@med.uoa.gr
1Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece;
2Hematology Department, Princess University Hospital, Madrid,
Spain;
3Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania;
4Department of Internal Medicine V, University of Heidelberg, Heidelberg,
Germany;
5Karmanos Cancer Institute, Wayne State University, Detroit, Michigan;
6Department of Medical Oncology, Duke University Medical Center, Durham,
North Carolina;
7Institute of Blood Pathology and Transfusion Medicine, Hematology Department of the Academy of Medical Sciences of Ukraine, Lviv, Ukraine;
8Division of Hematology-Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada;
9Clinical Research and Development, Oncology, Celgene Corporation,
Summit, New Jersey;
10Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Meletios Dimopoulos, Donna M. Weber, and Marta Olesnyckyj designed the study; Meletios Dimopoulos and Donna M. Weber wrote the report for the study;
Adrian Alegre, Edward A. Stadtmauer, Hartmut Goldschmidt, Jeffrey A. Zonder, Carlos M. de Castro, Zvenyslava Masliak, Donna Reece, and Meletios Dimopoulos
recruited patients for the study; and Zhinuan Yu performed the statistical analyses. All authors were involved in analyzing and interpreting the data and critically
reviewing the article content. The authors were fully responsible for content and editorial decisions for this article.
Cancer August 15, 2010 3807
Original ArticleRI is usually mild to moderate (ie, plasma creatinine >1.3
mg/dL and <2 mg/dL) in approximately 50%of patients;
however, severe RI (plasma creatinine  2 mg/dL) may be
observedin15%to 20%of patientsatdiagnosis.
3,5-7
Effective myeloma control and resultant reduction
in urinary light-chain excretion can lead to improvement
in RI in 50% to 60% of patients.
3,6,8,9 Although patients
with MM who have persistent RI often have inferior sur-
vival, recovery of renal function, often made possible
throughnoveldrugsthatbettercontrolthedisease,isasso-
ciated with an improvement in outcome.
4 In patients
with RI, drugs known as nephrotoxic should be avoided
whenever possible. Medications that are excreted renally
typically need dose and/or schedule adjustment to reduce
the riskofsideeffects.
10,11
Lenalidomide combined with dexamethasone is an
effective treatment for MM that provides an overall
response (OR) rate of 60% with a complete response
(CR) rate of 15%, in patients with relapsed and/or re-
fractory MM.
12,13 Two-thirds of lenalidomide is elimi-
nated unchanged through urinary excretion.
14 To our
knowledge, the retrospective analysis presented here is
the first to assess the impact of various degrees of renal
dysfunction on safety and efficacy outcomes with lenali-
domide, such as OR, time to progression (TTP), pro-
gression-free survival (PFS), overall survival (OS), and
improvements in renal function, in a large cohort of
patients with relapsed and/or refractory MM who
received lenalidomide.
MATERIALS AND METHODS
In total, 704 patients who met the entry criteria were
enrolled in MM-009 and MM-010, 2 large, phase 3,
randomized, multicenter clinical trials that compared
treatment with lenalidomide (25 mg daily on Days 1-
21 of each 28-day cycle) plus dexamethasone (40 mg on
Days 1-4, 9-12, and 17-20 every 28 days for 4 cycles
and 40 mg on Days 1-4 every cycle thereafter) versus
dexamethasone alone (identical schedule).
12,13 Treat-
ment was continued until patients developed either
unacceptable toxicity or disease progression. Toxicity
was graded according to the National Cancer Institute
Common Toxicity Criteria version 2.0, as reported
previously.
12,13
Three hundred fifty-three patients who were
randomized to receive lenalidomide plus dexamethasone
in these2trials
12,13wereincludedin thecurrentsubgroup
analysis. Inclusion and exclusion criteria were published
previously.
12,13 Entry criteria for renal function were
based on serum creatinine levels. All patients were
required to have a baseline serum creatinine level <2.5
mg/dL. Renal function was assessed throughout the
course of the study by measuring serum creatinine levels.
For the purpose of the present RI analysis, renal function
was assessed by using the serum creatinine level to calcu-
late creatinine clearance (CLCr) with the Cockroft-Gault
equation. Then, patients were subdivided into RI sub-
groups based on their CLCr values, defined as follows:
mild or no RI, CLCr  60 mL/minute; moderate RI, CLCr
 30 mL/minute and <60 mL/minute;or severe RI, CLCr
<30mL/minute.
15
The objective of the current analysis was to evalu-
ate the efficacy of therapy, safety, and tolerability with
lenalidomide plus dexamethasone in patients who had
mild or no RI compared with patients who had moder-
ate and severe RI. Response to treatment was assessed
according to the modified European Group for Blood
and Marrow Transplantation criteria for CR and par-
tial response (PR), according to criteria described by
the International Myeloma Working Group for a very
good PR (VGPR).
16,17 TTP was measured from the
date of randomization to the date of the first assess-
ment that identified disease progression. Patients who
died or discontinued the study without evidence of dis-
ease progression were censored at the last evaluation
for assessment of TTP. PFS was measured from the
date of randomization to the date of the first assess-
ment that identified disease progression or the date of
death during treatment, whichever occurred first.
Patients who were alive and discontinued study therapy
without evidence of disease progression were censored
at the last evaluation for assessment of PFS. OS was
measured from the date of randomization to the date
of death from any cause or was censored at the last fol-
low-up.
Data on OR (CR þ VGPR þ PR), TTP, and PFS
were assessed up to unblinding, which occurred in June
2005 for MM-009 and August 2005 for MM-010, for a
median follow-up duration of 17.5 months. The cutoff
for follow-up data on OS was January 2007, with a me-
dianfollow-updurationof31.3months.
Differences in OR rates were analyzed using conti-
nuity-corrected Pearson chi-square tests. Time-to-event
variables with censoring, including TTP, PFS, and OS,
were estimated by using the Kaplan-Meier method. Two-
sided log-rank tests were used for comparisons of TTP,
PFS,andOS.
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Baseline Characteristics
Of the 353 patients who were randomized to receive lena-
lidomide plus dexamethasone, baseline CLCr data were
available for 341 patients. Of these patients, 243 (71%)
hadmildor noRI (CLCr 60mL/minute),82(24%)had
moderate RI (CLCr  30 mL/minute and <60 mL/mi-
nute), and 16 (5%) had severe RI (CLCr <30 mL/mi-
nute). According to protocol exclusion criteria, all
patients who were included in this analysis had a relatively
low serum creatinine level (<2.5 mg/dL), although 16
patients had severe RI. Patients who had RI were older,
morelikelytobewomen,andhadhigherserumb2-micro-
globulin levels compared with patients who did not have
RI(allP<.05)(Table1).Besidesthis,renalfunctionsub-
groupswere balanced(Table1).
Efficacy
There were no statistical differences in OR rates between
the 3 subgroups (Table 2). Moreover, the quality of
response did not differ by severity of RI. A VGPR or bet-
ter was achieved in 34% of patients with mild or no RI, in
27%of patients withmoderateRI, and in 38%of patients
with severe RI (P ¼ not significant [NS] for both). The
TTP was similar in patients with mild or no RI (median,
12.0 months) and patients with moderate RI (median,
11.1 months) (Table 2). Patients who had severe RI had a
shorter TTP; however, the difference was not significant
compared with patients who had mild or no RI (median,
7.8 months; P ¼ NS). Similarly, PFS did not differ signif-
icantly between patients who had mild or no RI (median,
11.1 months) and patients who had moderate RI (me-
dian, 9.5 months; P ¼ NS) or severe RI (median, 7.8
months;P¼ NS)(Table2, Fig.1).
After a median follow-up of 31.3 months, OS was
38.9 months for patients who had mild or no RI (Table
2). Patientswho hadmoderate or severe RI tendedto have
shorter OS (29.0 months and 18.4 months, respectively),
and this was significantly shorter compared with the OS
of patients who had mild or no RI (P ¼ .006 for both)
(Table2,Fig. 2).
Improvement in Renal Function
Improvement in CLCr by at least 1 level (ie, mild or no
RI, moderate RI, or severe RI as described above; see
Materials and Methods) was experienced by 68 of 94
patients (72%) with moderate-to-severe RI who received
lenalidomide plus dexamethasone; whereas, of all those
who received lenalidomide plus dexamethasone, only 3
patients (1%) had a worsening CLCr by at least 1 level
(Table3).
Safety
Neutropenia was the most common grade 3 or 4 hemato-
logic adverse event, and the rates of neutropenia were sim-
ilaracross all subgroupsofrenal function (32%,48%,and
38% of patients with mild or no RI, moderate RI, and
severe RI, respectively) (Table 4). Renal impairment was
not associated with a higher incidence of fever or
Table 1. Baseline Characteristics of Patients
Characteristic Mild or No
RI: CLCr ‡60
mL/min
Moderate RI:
CLCr ‡30
mL/min
to <60 mL/min
Severe RI:
CLCr <30
mL/min
No. of patients 243 82 16
Median age (range), y 61 (33-82) 69 (38-84)
a 73 (56-86)
a
Men, % 67 43
a 25
a
ECOG score 0 or 1, % 89 87 69
Median time since diagnosis (range), y 3.1 (0.4-15.7) 3.4 (0.5-14.6) 3.4 (1.0-8.7)
Bone lesions, % 75 72 69
Serum b2-microglubulin >2.5 mg/L, % 62 89
a 100
a
Immunoglobulin G, % 66 63 56
Immunoglobulin A, % 21 20 19
Durie-Salmon stage III, % 62 72 75
No. of prior lines of therapy, median (range) 2 (0-8) 2 (0-5) 2 (0-3)
Prior therapies, %
Thalidomide 35 33 56
Bortezomib 96 0
RI indicates renal impairment; CLCr, creatinine clearance; ECOG, Eastern Cooperative Oncology Group.
aP <.05 versus patients with mild or no RI.
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increased incidence of pneumonia unrelated to neutrope-
nia in the limited number of patients with severe RI
(Table 4). Thrombocytopenia was significantly more
common in patients with severe RI (38%; P < .05) and
moderate RI (22%; P < .05) than in patients with mild or
no RI (9%). Grade 3 or 4 thrombotic events occurred in
patients with mild or no RI (13%), moderate RI (15%),
and severeRI(6%)(Table4).
All patients received a starting lenalidomide dose of
25 mg. The median dose of lenalidomide was 25 mg for
patients with moderate or better RI and 15 mg for
patients with severe RI (Table 5). Significantly more
Table 2. Efficacy Outcomes According to Renal Function
No. of Patients (%)
Outcome Mild or No
RI: CLCr ‡60
mL/min
Moderate RI:
CLCr ‡30
mL/min to <60
mL/min
Severe RI:
CLCr <30
mL/min
Total no. of patients 243 82 16
Response
Overall response 156 (64) 46 (56) 8 (50)
Complete response 38 (16) 13 (16) 1 (6)
Very good partial response 45 (19) 9 (11) 5 (31)
Partial response 73 (30) 24 (29) 2 (13)
Stable disease 69 (28) 28 (34) 5 (31)
Progressive disease 5 (2) 3 (4) 0
Response not evaluable
a 13 (5) 5 (6) 3 (19)
Efficacy, mo
Median time to progression 12.0 11.1 7.8
Median PFS 11.1 9.5 7.8
Median OS 38.9 29.0
b 18.4
b
RI indicates renal impairment; CLCr, creatinine clearance; PFS, progression-free survival; OS, overall survival.
aP ¼.006 versus patients with mild or no RI.
bIncluding patients who did not have any response assessment data at the data cutoff point or whose only assessment
was ‘‘response not evaluable.’’
Figure 1. This is a Kaplan-Meier plot of progression-free sur-
vival according to renal impairment (RI). RI was defined by
creatinine clearance (CLCr) level as mild or no RI (CLCr  60
mL/minute), moderate RI (CLCr from  30 mL/minute to <60
mL/minute), or severe RI (CLCr <30 mL/minute).
Figure 2. This is a Kaplan-Meier plot of overall survival
according to renal impairment (RI). P < .01 for patients with
severe RI compared with patients with mild or no RI. RI was
defined according to the creatinine clearance (CLCr) level as
mild or no RI (CLCr  60 mL/minute), moderate RI (CLCr from
 30 mL/minute to <60 mL/minute), or severe RI (CLCr <30
mL/minute).
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No. of Patients (%)
Renal Function
at Baseline
Mild or No
RI: CLCr ‡60
mL/min
Moderate
RI: CLCr ‡30
mL/min to
<60 mL/min
Severe
RI: CLCr <30
mL/min
Mild or no RI, n¼238 235 (99) 1 (0.5) 2 (1)
Moderate RI, n¼80 56 (70)
a 24 (30) 0 (0)
Severe RI, n¼14 0 (0) 12 (86)
a 2 (14)
Total, N¼332 291 (88) 37 (11) 4 (1)
RI indicates renal impairment; CLCr, creatinine clearance.
aThese patients improved with treatment. The best postbaseline renal responses were used.
Table 4. Grade 3 or 4 Adverse Events According to Renal Function That Occurred in >10% of
Patients
Adverse Event Mild or No
RI: CLCr
‡60 mL/min
Moderate
RI: CLCr ‡30
mL/min to
<60 mL/min
Severe RI:
CLCr <30
mL/min
Total no. of patients 243 82 16
Hematologic toxicities, %
Neutropenia 32 48
a 38
Thrombocytopenia 92 2
a 38
a
Anemia 52 1
a 44
a
Nonhematologic toxicities, %
Thrombotic events
b 13 15 6
Hypertension NOS 0.8 2 13
Atrial fibrillation 34 1 3
Fatigue 51 2
a 0
Asthenia 45 1 3
Constipation 21 1 3
Hypocalcemia 36 1 9
Dehydration 0.8 2
a 13
a
Pneumonia NOS 79 2 5
a
Clinically important adverse events, %
Febrile neutropenia 32 0
Neuropathy 22 0
Peripheral neuropathy 21 0
RI indicates renal impairment; CLCr, creatinine clearance; NOS, not otherwise specified.
aP <.05 versus patients with mild or no RI.
bThrombotic events included pulmonary embolism, deep vein thrombosis, and venous thrombosis NOS.
Table 5. Dosage Information According to Renal Function
Variable Mild or No
RI: CLCr ‡60
mL/min
Moderate
RI: CLCr ‡30
mL/min to
<60 mL/min
Severe
RI: CLCr <30
mL/min
Total no. of patients 243 82 16
Median lenalidomide dose, mg/d 25 25 15
a
Dose reduction/interruption because
of AE, %
22 40
a 38
a
Median time to lenalidomide dose
reduction (range), d
99 (29-486) 85 (29-561) 78 (29-374)
Discontinuation because of AE, % 12 18 38
a
RI indicates renal impairment; CLCr, creatinine clearance; AE, adverse event.
aP <.05 versus patients with mild or no RI.
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required a lenalidomide dose reduction or interruption
because of adverse events than patients with mild or no RI
(22%; P < .05). The median time to lenalidomide dose
reduction was 99 days, 85 days, and 78 days for patients
with mild or no RI, moderate RI, and severe RI, respec-
tively. Overall, lenalidomide discontinuation because of
adverse events (in almost all patients because of cytope-
nias) increased with the severity of RI and was signifi-
cantly more frequent for patients with severe RI (38%)
than forpatientswithmildorno RI(12%;P< .05).
DISCUSSION
Renal impairment is a frequent complication in patients
with MM, and its incidence increases in patients with
recurrent disease and as the disease becomes refractory to
treatment.
1 Two large, prospective randomized trials,
MM-009 and MM-010, established the significant activ-
ity of combination lenalidomide plus dexamethasone in
patients with relapsed and/or refractory MM.
12,13
Although lenalidomide is excreted renally, many patients
with advanced myeloma and RI may not have any other
treatment option. This frequent clinical complication
prompted a retrospective analysis of data from MM-009
and MM-010 to evaluate the effects of RI on patient out-
comes. The results from the current subgroup analysis
demonstrate that the combination of lenalidomide plus
dexamethasone is effective in patients with all degrees of
renal dysfunction. Renal impairment at the time of diag-
nosis is associated with poor survival in patients with
MM.
6,9 Persistent renal failure is associated with an
increased risk of morbidity and early mortality.
18,19 In 1
study, the median survival was an additional 6 months for
patients who had reversible renal failure compared with
patients who had irreversible renal injury, indicating that
renal improvement may be associated with improved
long-term survival.
6 Thus, the reversibility of renal failure
may be an important prognostic factor, perhaps as impor-
tant as quality of response to therapy, for patients with
RI.
6,9 The improvement in RI to a near-normal range
(CLCr  60 mL/minute) observed in the majority of
patients in the current study suggests that lenalidomide
plus dexamethasone may be a particularly useful therapy
inthissetting.
In the current study, TTP and PFS did not differ
significantly between patients who had mild or no RI
compared with patients who had RI. However, patients
who had severe RI (CLCr <30 mL/minute) tended to
have shorter PFS and a trend toward shorter TTP.
Patients who had moderate or severe RI had significantly
shorter OS (29.0 months and 18.4 months, respectively)
compared with patients who had mild or no RI (38.9
months; P ¼ .006 for both). Furthermore, more patients
who had severe RI discontinued therapy because of
adverse events (predominantly cytopenias). These differ-
ences may be associated with treatment schedule: Patients
with moderate RI received a median daily dose of 25 mg,
similar to patients with mild or no RI, and patients with
severe RI received a median daily dose of 15 mg; thus,
patients with severe RI may have received longer treat-
ment and greater benefit at a lower starting and treatment
dose, consistent with the recent dosing adjustment recom-
mendations forthispatientpopulation(Table6).
The time to dose reduction appeared to be shorter
for patients who had RI compared with patients who had
mild or no RI, and those who had moderate or severe RI
required significantly more frequent intervention because
of anemia and thrombocytopenia than those with mild or
no RI. Although thrombocytopenia was more pro-
nounced, there were no bleeding events. Other adverse
events generally occurred with similar frequencies in
patientswithand withoutRI.
The current study highlights the limitations of using
the serum creatinine level as a measure of patient renal
function, because a subset of eligible patients (serum
Table 6. Recommendations for Lenalidomide Dosing in Patients With Multiple Myeloma Who Have
Renal Impairment
a
Category Renal Function
b Lenalidomide Dosing in
Multiple Myeloma
Moderate RI CLCr  30 mL/min to <60 mL/min 10 mg every 24 h
Severe RI CLCr <30 mL/min (not requiring dialysis) 15 mg every 48 h
End-stage renal disease CLCr <30 mL/min (requiring dialysis) 5 mg once daily; on dialysis days,
dose should be administered after dialysis
RI indicates renal impairment; CLCr, creatinine clearance.
aSee Celegene Corporation 2009.
20,21
bCockcroft-Gault CLCr.
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minute) and a greater frequency of certain treatment-
related adverse events. Because renal clearance may be
reduced by 35% to 50% without evidence of renal disease
in elderly patients, dosage adjustments are necessary for
renally excreted drugs. In addition, because creatinine
production is lowerin elderlyindividuals due todecreased
muscle mass and because serum creatinine may be normal
despite impaired CLCr, it is recommended to base dosage
adjustments on CLCr instead of serum creatinine (Table
6).
20 By using CLCr as a guide for dosing patients with
MM who have RI, Chen and colleagues
14 studied the
effect of RI on the pharmacokinetics of lenalidomide after
a single 25-mg oral dose (patients aged 39-76 years) in
patients without cancer. Those authors demonstrated
that, in study participants who had increased baseline RI,
renal lenalidomide clearance decreased substantially, pro-
longing its half-life by approximately 6 to 12 hours.
14 An
80% decrease in lenalidomide clearance was observed in
patients with RI compared with healthy individuals, and
that decrease corresponded to the primary renal route of
drug excretion.
14 Since this analysis, adjustments to the
initial dose of lenalidomide have been recommended in
patients with moderate RI (CLCr  30 mL/minute and
<60mL/minute)or severe RI (CLCr <30 mL/minute not
requiring dialysis) and end-stage renal failure (CLCr  30
mL/minute and <60 mL/minute requiring dialysis). On
the basis of a pharmacokinetic study in patients who had
RI caused by nonmalignant conditions, the recommenda-
tions for the starting dose of lenalidomide in patients with
MM who have RI to maintain appropriate exposure are
shownin Table6.
20,21
In conclusion, lenalidomide plus dexamethasone led
to improvement in RI in the majority of patients in the
current analysis. With careful monitoring of CLCr levels
and adverse events and with appropriate dose adjust-
ments, lenalidomide plus dexamethasone is a highly effec-
tive treatment and is well tolerated in patients with MM
who have RI. Platelet counts also should be monitored
carefully, because we observed more marked thrombocy-
topenia in patients who had a CLCr <30 mL/minute,
although there did not appear to be any increased inci-
dence of bleeding in the 16 patients in the current study.
Formal studies confirming the efficacy of lenalidomide in
patients with renal failure are warranted and ongoing.
Currently, 2 trials are recruiting for the study of lenalido-
mide treatment in patients with MM who have RI. These
include a study of the pharmacokinetics of lenalidomide
in patients with MM who have RI (National Clinical
Trial [NCT] 00779922) and a phase 1/2 trial of lenalido-
mide plus low-dose dexamethasone in patients with
relapsed and/or refractory MM and RI (NCT00790842).
For future studies and therapy with lenalidomide, it is im-
portant to convert serum creatinine to CLCr and to use
CLCr for dosage adjustments, as recommended in Table
6, forpatientswithRI.
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